Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.11 +2.5%	$3.76	$2.12 ▼ $5.80	$399.89M	1.99	1.02 million shs	6.11 million shs
ETON Eton Pharmaceuticals	$16.70 -2.5%	$14.83	$3.87 ▼ $21.48	$459.12M	1.13	381,790 shs	528,523 shs
ONCY Oncolytics Biotech	$0.94 -7.8%	$0.90	$0.33 ▼ $1.53	$99.36M	1.09	914,715 shs	690,937 shs
VIGL Vigil Neuroscience	$8.05	$8.00	$1.31 ▼ $8.10	$383.91M	3.33	1.09 million shs	N/A

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	+6.08%	+0.50%	-0.50%	+68.49%	+2.30%
ETON Eton Pharmaceuticals	-1.15%	+12.19%	+17.74%	-13.10%	+354.11%
ONCY Oncolytics Biotech	+18.56%	+9.68%	-15.00%	+103.88%	+12.05%
VIGL Vigil Neuroscience	0.00%	0.00%	-0.25%	+246.98%	+171.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQST Aquestive Therapeutics	2.062 of 5 stars	3.5	3.0	3.0	0.0	0.0
ETON Eton Pharmaceuticals	2.3236 of 5 stars	3.5	1.0	3.0	1.7	0.6
ONCY Oncolytics Biotech	1.6981 of 5 stars	3.4	3.0	1.9	0.0	0.0
VIGL Vigil Neuroscience	3.4342 of 5 stars	4.0	3.0	2.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	3.00	Buy	$10.14	146.78% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	77.64% Upside
ONCY Oncolytics Biotech	2.80	Moderate Buy	$5.00	431.75% Upside
VIGL Vigil Neuroscience	2.00	Hold	$10.80	34.16% Upside

Current Analyst Ratings Breakdown

Latest ONCY, VIGL, AQST, and ETON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	ONCY Oncolytics Biotech	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$7.00
6/17/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/2/2025	AQST Aquestive Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00
5/28/2025	VIGL Vigil Neuroscience	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$11.00 ➝ $8.00
5/27/2025	VIGL Vigil Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$14.00 ➝ $8.00
5/23/2025	VIGL Vigil Neuroscience	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Neutral	$8.00
5/22/2025	VIGL Vigil Neuroscience	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$57.56M	7.12	N/A	N/A	($0.73) per share	-5.63
ETON Eton Pharmaceuticals	$39.01M	11.48	N/A	N/A	$0.89 per share	18.76
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.05 per share	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	$1.75 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$44.14M	-$0.70	N/A	N/A	N/A	-147.38%	N/A	-63.87%	N/A
ETON Eton Pharmaceuticals	-$3.82M	-$0.16	N/A	33.40	N/A	-7.10%	-0.73%	-0.22%	N/A
ONCY Oncolytics Biotech	-$23.14M	-$0.27	N/A	N/A	N/A	N/A	-438.11%	-143.90%	N/A
VIGL Vigil Neuroscience	-$84.26M	-$2.05	N/A	N/A	N/A	N/A	-111.70%	-74.67%	N/A

Latest ONCY, VIGL, AQST, and ETON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	AQST Aquestive Therapeutics	-$0.18	-$0.14	+$0.04	-$0.14	$11.32 million	$10.00 million
8/8/2025	Q2 2025	ONCY Oncolytics Biotech	-$0.11	-$0.05	+$0.06	-$0.05	N/A	N/A
8/7/2025	Q2 2025	ETON Eton Pharmaceuticals	-$0.01	-$0.10	-$0.09	-$0.10	$16.71 million	$18.93 million
5/14/2025	Q1 2025	ONCY Oncolytics Biotech	-$0.09	-$0.06	+$0.03	-$0.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	3.53	4.48
ETON Eton Pharmaceuticals	1.14	1.77	1.16
ONCY Oncolytics Biotech	N/A	2.88	3.20
VIGL Vigil Neuroscience	N/A	2.97	2.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
ETON Eton Pharmaceuticals	27.86%
ONCY Oncolytics Biotech	6.82%
VIGL Vigil Neuroscience	83.64%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	8.35%
ETON Eton Pharmaceuticals	16.03%
ONCY Oncolytics Biotech	0.10%
VIGL Vigil Neuroscience	18.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	99.72 million	91.40 million	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.52 million	Optionable
ONCY Oncolytics Biotech	30	97.41 million	97.31 million	Not Optionable
VIGL Vigil Neuroscience	40	47.69 million	39.10 million	Not Optionable

ONCY, VIGL, AQST, and ETON Headlines

Recent News About These Companies

Vigil Neuroscience Inc Merger and Leadership Changes

August 13 at 5:51 AM | theglobeandmail.com

Blair William & Co. IL Raises Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

August 10, 2025 | marketbeat.com

Brokerages Set Vigil Neuroscience, Inc. (NASDAQ:VIGL) PT at $10.80

August 9, 2025 | americanbankingnews.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Average Recommendation of "Hold" from Brokerages

August 6, 2025 | marketbeat.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Significant Growth in Short Interest

August 3, 2025 | marketbeat.com

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL

July 14, 2025 | businesswire.com

Vigil Neuroscience, Inc. (VIGL) Cash Flow - Yahoo Finance

July 2, 2025 | finance.yahoo.com

Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High? - Nasdaq

June 27, 2025 | nasdaq.com

Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?

June 25, 2025 | zacks.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders

June 9, 2025 | prnewswire.com

Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet

June 9, 2025 | zacks.com

Vigil Neuroscience halts Phase 2 trial for ALSP treatment

June 5, 2025 | investing.com

Vigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II Trial

June 5, 2025 | biospace.comB

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors ...

June 5, 2025 | morningstar.comM

Disappointing results see Vigil Neuro drop iluzanebart development

June 4, 2025 | thepharmaletter.comT

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm

June 4, 2025 | prnewswire.com

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

June 4, 2025 | globenewswire.com

Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?

June 2, 2025 | zacks.com

Stifel cuts Vigil Neuroscience stock rating, lowers target to $8

May 29, 2025 | investing.com

Stifel Downgrades Vigil Neuroscience (VIGL)

May 29, 2025 | msn.com

HC Wainwright & Co. Downgrades Vigil Neuroscience (VIGL)

May 28, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, VIGL, AQST, and ETON Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$4.11 +0.10 (+2.49%)

Closing price 04:00 PM Eastern

Extended Trading

$4.11 0.00 (0.00%)

As of 07:56 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Eton Pharmaceuticals NASDAQ:ETON

$16.70 -0.42 (-2.45%)

Closing price 04:00 PM Eastern

Extended Trading

$16.71 +0.01 (+0.06%)

As of 04:20 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Oncolytics Biotech NASDAQ:ONCY

$0.94 -0.08 (-7.81%)

Closing price 04:00 PM Eastern

Extended Trading

$0.98 +0.04 (+4.12%)

As of 07:56 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Vigil Neuroscience NASDAQ:VIGL

$8.05 0.00 (0.00%)

As of 08/5/2025

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time